Retina Consultants San Diego Opens Enrollment in GA Clinical Trial With Apellis
Retina Consultants San Diego (RCSD) has been selected to participate in the Gallop Phase 2 geographic atrophy clinical trial in collaboration with Apellis Pharmaceuticals. RCSD is among a limited number of sites helping evaluate innovative combination therapy for geographic atrophy (GA), a late stage of age-related macular degeneration.
Gallop, a Phase 2, randomized, placebo-controlled, multicenter, masked study, investigates the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syfovre/Pegcetacoplan (APL-2) in patients diagnosed with geographic atrophy secondary to AMD.
About the Gallop Clinical Trial
Study Phase: Phase 2
Design: Randomized, placebo-controlled, masked, parallel-group, multicenter study
Sponsor: Apellis Pharmaceuticals, Inc.
Study Objective: Evaluate whether the combination of APL-3007 and Syfovre/Pegcetacoplan (APL-2) can safely and effectively slow the progression of GA compared with placebo in eligible participants.
Key Features
Estimated Enrollment: ~240 participants
Start Date: June 23, 2025
Estimated Completion: November 30, 2027
Study Arms & Interventions
Combination Therapy Arm: Participants receive APL-3007 plus Syfovre/Pegcetacoplan (APL-2) according to the study protocol.
Placebo Arm: Participants receive placebo injections matching the trial schedule
Eligibility Overview
Participants must be diagnosed with geographic atrophy secondary to AMD and meet imaging and clinical criteria, including lesion size requirements and prior Syfovre treatment history as defined by the central reading center.
Outcome Measures
Primary Outcome: Assess changes in anatomical and clinical measures of GA lesion progression.
Secondary Outcomes: Evaluate safety, tolerability, pharmacodynamics, and other exploratory endpoints related to disease progression and visual function.
View full study details on clinicaltrials.gov
Interested in joining?
Contact RCSD today to learn more about more about eligibility and enrollment opportunities for the Gallop GA clinical trial in San Diego.